{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:50:57Z","timestamp":1791305457840,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11095-026-04156-7","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:18:08Z","timestamp":1784049488000},"page":"3377-3391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spray-Dried Formulations of Relaxin-H2 for Inhalation"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-7640","authenticated-orcid":false,"given":"Danforth P.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nani P.","family":"Kadrichu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Tarara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Kuehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8473-1625","authenticated-orcid":false,"given":"Jeffry G.","family":"Weers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"4156_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/labinvest.2010.198","volume":"91","author":"CS Samuel","year":"2011","unstructured":"Samuel CS, Cendrawan S, Gao X-M, Ming Z, Zhao C, Kiriazis H, et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest. 2011;91:675\u201390. https:\/\/doi.org\/10.1038\/labinvest.2010.198.","journal-title":"Lab Invest"},{"key":"4156_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrcardio.2009.198","volume":"7","author":"X-J Du","year":"2010","unstructured":"Du X-J, Bathgate RAD, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2010;7:48\u201358. https:\/\/doi.org\/10.1038\/nrcardio.2009.198.","journal-title":"Nat Rev Cardiol"},{"key":"4156_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10741-008-9129-3","volume":"14","author":"SL Teichman","year":"2009","unstructured":"Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, Felker GM, Metra M, Cotter G. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009;14:321\u20139. https:\/\/doi.org\/10.1007\/s10741-008-9129-3.","journal-title":"Heart Fail Rev"},{"key":"4156_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","volume":"373","author":"JR Teerlink","year":"2009","unstructured":"Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(09)60622-X.","journal-title":"Lancet"},{"key":"4156_CR5","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/eurjhf\/hfq132","volume":"12","author":"M Metra","year":"2010","unstructured":"Metra M, Teerlink JR, Felker GM, et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail. 2010;12:1130\u20139. https:\/\/doi.org\/10.1093\/eurjhf\/hfq132.","journal-title":"Eur J Heart Fail"},{"key":"4156_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(12)61855-8.","journal-title":"Lancet"},{"key":"4156_CR7","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1801291","volume":"381","author":"M Metra","year":"2019","unstructured":"Metra M, Teerlink JR, Cotter G, et al. Effects of serelaxin in patients with acute heart failure. N Engl J Med. 2019;381:716\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1801291.","journal-title":"N Engl J Med"},{"key":"4156_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1023\/A:1018901009062","volume":"10","author":"SA Chen","year":"1993","unstructured":"Chen SA, Perlman AJ, Spanski N, et al. The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration. Pharm Res. 1993;10:834\u20138. https:\/\/doi.org\/10.1023\/A:1018901009062.","journal-title":"Pharm Res"},{"key":"4156_CR9","doi-asserted-by":"publisher","first-page":"P505","DOI":"10.1016\/j.amjcard.2017.04.056","volume":"120","author":"PA McCullough","year":"2017","unstructured":"McCullough PA. How trialists and pharmaceutical sponsors have failed us by thinking that acute heart failure is a 48-hour illness. Am J Cardiol. 2017;120:P505\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2017.04.056.","journal-title":"Am J Cardiol"},{"key":"4156_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00392-023-02305-1","volume":"113","author":"N Almeida-Pinto","year":"2024","unstructured":"Almeida-Pinto N, Dschietzig TB, Bras-Silva C, Adao R. Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives. Clin Res Cardiol. 2024;113:1137\u201350. https:\/\/doi.org\/10.1007\/s00392-023-02305-1.","journal-title":"Clin Res Cardiol"},{"key":"4156_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jchf.2019.08.005","volume":"7","author":"CM O\u2019Connor","year":"2019","unstructured":"O\u2019Connor CM. Acute decompensated heart failure \u2013 Is there a path forward? J Am Coll Cardiol HF. 2019;7:911\u20132. https:\/\/doi.org\/10.1016\/j.jchf.2019.08.005.","journal-title":"J Am Coll Cardiol HF"},{"key":"4156_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ejhf.1692","volume":"22","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR, Davison BA, Cotter G, et al. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. Eur J Heart Fail. 2020;22:315\u201329. https:\/\/doi.org\/10.1002\/ejhf.1692.","journal-title":"Eur J Heart Fail"},{"key":"4156_CR13","doi-asserted-by":"publisher","unstructured":"Batool A, Salehi N, Chaudry S, Cross M, Malkawi A, Siraj A. Role of vasodilator therapy in acute heart failure. Cureus. 2021;13:e17126.https:\/\/doi.org\/10.7759\/cureus.17126.","DOI":"10.7759\/cureus.17126"},{"key":"4156_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bep.2021.114884","volume":"197","author":"CS Samuel","year":"2022","unstructured":"Samuel CS, Bennett RG. Relaxin as an anti-fibrotic treatment: perspectives, treatments, challenges, and future directions. Biochem Pharmacol. 2022;197: 114884. https:\/\/doi.org\/10.1016\/j.bep.2021.114884.","journal-title":"Biochem Pharmacol"},{"key":"4156_CR15","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/bph.16055","volume":"180","author":"P Verdino","year":"2023","unstructured":"Verdino P, Lee SL, Cooper FN, et al. Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure. Br J Pharmacol. 2023;180:1965\u201380. https:\/\/doi.org\/10.1111\/bph.16055.","journal-title":"Br J Pharmacol"},{"key":"4156_CR16","doi-asserted-by":"publisher","unstructured":"Erlandson SC, Wang J, Jiang H, Rockman HA, Kruse AC. Engineering and characterization of a long half-life receptor RXFP1 agonist. bioRxiv. 2022.  https:\/\/doi.org\/10.1101\/2022.04.19.488796 .04.19.488796.","DOI":"10.1101\/2022.04.19.488796"},{"key":"4156_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114370","volume":"160","author":"F Alam","year":"2023","unstructured":"Alam F, Gaspari TA, Kemp-Harper BK, et al. The single-chain relaxin mimetic, B7\u201333, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. Biomed Pharm. 2023;160: 114370. https:\/\/doi.org\/10.1016\/j.biopha.2023.114370.","journal-title":"Biomed Pharm"},{"key":"4156_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67\u201374. https:\/\/doi.org\/10.1038\/nrd2153.","journal-title":"Nat Rev Drug Discov"},{"key":"4156_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1513\/pats.200409-049TA","volume":"1","author":"JS Patton","year":"2004","unstructured":"Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1:338\u201344. https:\/\/doi.org\/10.1513\/pats.200409-049TA.","journal-title":"Proc Am Thorac Soc"},{"key":"4156_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1089\/jamp.2018.1497","volume":"32","author":"JG Weers","year":"2019","unstructured":"Weers JG, Son Y-J, Glusker M, Haynes A, Huang D, Kadrichu N, Le J, Li X, Malcolmson R, Miller DP, Tarara TE, Ung K, Clark A. Idealhalers versus realhalers: is it possible to bypass deposition in the upper respiratory tract. J Aerosol Med Pulm Drug Deliv. 2019;32:58\u201369. https:\/\/doi.org\/10.1089\/jamp.2018.1497.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"4156_CR21","unstructured":"Ung KT, Weers JG, Huang D, Rao N, Son YJ. Targeted delivery of spray-dried formulations to the lungs. United States patent application US 15\/758,643. 2018."},{"key":"4156_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0021-8502(99)00547-9","volume":"31","author":"KW Stapleton","year":"2000","unstructured":"Stapleton KW, Guentsch E, Hoskinson MK, Finlay WH. On the suitability of the k-e turbulence model for aerosol deposition in the mouth and throat: a comparison with experiments. J Aerosol Sci. 2000;31:739\u201349. https:\/\/doi.org\/10.1016\/S0021-8502(99)00547-9.","journal-title":"J Aerosol Sci"},{"key":"4156_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0021-8502(03)00387-2","volume":"35","author":"B Grgic","year":"2004","unstructured":"Grgic B, Finlay WH, Heenan AF. Regional aerosol deposition and flow measurements in an idealized mouth and throat. J Aerosol Sci. 2004;35:21\u201332. https:\/\/doi.org\/10.1016\/S0021-8502(03)00387-2.","journal-title":"J Aerosol Sci"},{"key":"4156_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/jamp2021.29057.lg","volume":"35","author":"L Golshahi","year":"2022","unstructured":"Golshahi L, Finlay WH, Wachtel H. Use of airway replicas in lung delivery applications. J Aerosol Med Pulm Drug Deliv. 2022;35:61\u201372. https:\/\/doi.org\/10.1089\/jamp2021.29057.lg.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"4156_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11095-016-2050-x","volume":"34","author":"J Weers","year":"2017","unstructured":"Weers J, Clark A. The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers. Pharm Res. 2017;34:507\u201328. https:\/\/doi.org\/10.1007\/s11095-016-2050-x.","journal-title":"Pharm Res"},{"key":"4156_CR26","unstructured":"Tarara T, Lyons S, Miller D, Citterio M, Franza M, Burke M, Weers J (2024) Minimization of flow rate dependence of dry powder inhalers (DPIs) by tuning device resistance. Inhalation Magazine. https:\/\/www.inhalationmag.com\/article\/minimization-of-flow-rate-dependence-of-dry-powder-inhalers-dpis-by-tuning-device-resistance\/"},{"key":"4156_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0021-8502(94)90189-9","volume":"25","author":"AR Clark","year":"1994","unstructured":"Clark AR, Egan M. Modelling the deposition of inhaled powdered drug aerosols. J Aerosol Sci. 1994;25:175\u201386. https:\/\/doi.org\/10.1016\/0021-8502(94)90189-9.","journal-title":"J Aerosol Sci"},{"key":"4156_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/17425247.2024.2343894","volume":"21","author":"JG Weers","year":"2024","unstructured":"Weers JG. Design of dry powder inhalers to improve patient outcomes: it\u2019s not just about the device. Expert Opin Drug Deliv. 2024;21:365\u201380. https:\/\/doi.org\/10.1080\/17425247.2024.2343894.","journal-title":"Expert Opin Drug Deliv"},{"key":"4156_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111855","volume":"13","author":"DP Miller","year":"2021","unstructured":"Miller DP, Tarara TE, Weers JG. Targeting of inhaled therapeutics to the small airways: nanoleucine carrier formulations. Pharmaceutics. 2021;13: 1855. https:\/\/doi.org\/10.3390\/pharmaceutics13111855.","journal-title":"Pharmaceutics"},{"key":"4156_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.addr.2020.05.003","volume":"165\u2013166","author":"S Sahakijpijarn","year":"2020","unstructured":"Sahakijpijarn S, Smyth H, Miller D, Weers J. Post-inhalation cough with therapeutic aerosols: Formulation considerations. Adv Drug Deliv Rev. 2020;165\u2013166:127\u201341. https:\/\/doi.org\/10.1016\/j.addr.2020.05.003.","journal-title":"Adv Drug Deliv Rev"},{"key":"4156_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/0192623320946297","volume":"49","author":"RK Wolff","year":"2021","unstructured":"Wolff RK. Perspective on lung dose of inhaled biomolecules. Toxicol Pathol. 2021;49:378\u201385. https:\/\/doi.org\/10.1177\/0192623320946297.","journal-title":"Toxicol Pathol"},{"key":"4156_CR32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","volume":"60","author":"SI Rennard","year":"1986","unstructured":"Rennard SI, Basset G, Lecossier D, O\u2019Donnell KM, Pinkston P, Martin PG, Crystal RG. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J Appl Physiol. 1986;60:532\u20138. https:\/\/doi.org\/10.1152\/jappl.1986.60.2.532.","journal-title":"J Appl Physiol"},{"key":"4156_CR33","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.cardfail.2016.06.051","volume":"22","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Saini R, Gullestad L, Descotes J, Masior T, Wang Y, Pak J, Pang Y, Unemori E, Severin T. RELAX-REPEAT: a multicenter, prospective, randomized, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure. J Card Fail. 2016;22:S14\u20135.","journal-title":"J Card Fail"},{"key":"4156_CR34","first-page":"69","volume":"1","author":"CL Leach","year":"2004","unstructured":"Leach CL, Kuo M-C, Bueche B, Fishburn S, Viegas T, Bossard M, Guo L, Bentley MD, Hobbs CH, Cherrington AD, Patton JS. Modifying the pulmonary absorption and retention of proteins through PEGylation. Proc Respir Drug Deliv IX. 2004;1:69\u201377.","journal-title":"Proc Respir Drug Deliv IX"},{"key":"4156_CR35","unstructured":"Poterski RS. Synthesis of recombinant human relaxin H2 in bacteria and its effects on differentiation of carcinoembryonic stem cells. Ph.D. Thesis, University of Guelph, Ontario, Canada, 2017, p.98."},{"key":"4156_CR36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1183\/09031936.00141514","volume":"45","author":"PS Hiemstra","year":"2015","unstructured":"Hiemstra PS, McCray PB, Bals R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J. 2015;45:1150\u201362. https:\/\/doi.org\/10.1183\/09031936.00141514.","journal-title":"Eur Respir J"},{"key":"4156_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/0192623320943129","volume":"49","author":"TD Flandre","year":"2021","unstructured":"Flandre TD, Hey AS, Spence FJ. Nonclinical safety assessment of an inhaled formulation of serelaxin: a recombinant human protein in rats and cynomolgus monkeys (Macaca fascicularis). Toxicol Pathol. 2021;49:286\u201395. https:\/\/doi.org\/10.1177\/0192623320943129.","journal-title":"Toxicol Pathol"},{"key":"4156_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.addr.2014.02.001","volume":"71","author":"B Forbes","year":"2014","unstructured":"Forbes B, O\u2019Lone R, Allen PP, et al. Challenges for inhaled drug discovery and development: Induced alveolar macrophages responses. Adv Drug Deliv Rev. 2014;71:15\u201333. https:\/\/doi.org\/10.1016\/j.addr.2014.02.001.","journal-title":"Adv Drug Deliv Rev"},{"issue":"Suppl 5","key":"4156_CR39","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1289\/ehp.97105s51231","volume":"105","author":"KJ Nikula","year":"1997","unstructured":"Nikula KJ, Avila KJ, Griffith WC, Mauderly JL. Sites of particle retention and lung tissue responses to chronically inhaled diesel exhaust and coal dust in rats and cynomolgous monkeys. Environ Health Perspect. 1997;105(Suppl 5):1231\u20134.","journal-title":"Environ Health Perspect"},{"key":"4156_CR40","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/1091581815624080","volume":"35","author":"JS Tepper","year":"2016","unstructured":"Tepper JS, Kuehl PJ, Cracknell S, Nikula KJ, Pei L, Blanchard JD. Symposium summary: Breathe in, breathe out, it\u2019s easy: What you need to know about developing inhaled drugs. Int J Toxicol. 2016;35:376\u201392. https:\/\/doi.org\/10.1177\/1091581815624080.","journal-title":"Int J Toxicol"},{"key":"4156_CR41","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1172\/JC119099","volume":"98","author":"E Unemori","year":"1996","unstructured":"Unemori E, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, Amento EP. Relaxin induces extracellular-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest. 1996;98:2739\u201345. https:\/\/doi.org\/10.1172\/JC119099.","journal-title":"J Clin Invest"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04156-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04156-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04156-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:54:23Z","timestamp":1791302063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04156-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04156-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DPM, NPK, TET, and JGW were employees of Novartis Pharmaceutical Corp. (San Carlos, CA) during conduct of portions of this work. PJK was employed by Lovelace Biomedical Research Institute (Albuquerque, NM). JSP led the rat pharmacokinetics study at Inhale Therapeutic Systems (San Carlos, CA). We all\u00a0have been working on the design and development of inhaled products for more than 20 years, receiving wages and other forms of compensation during that time.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest related to this study.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}